856 INBRX-106: a novel hexavalent anti-OX40 agonist for the treatment of solid tumors

• Quinn Deveraux,
• Heather Kinkead,
• Kyle Jones,
• Bryan Becklund,
• Florian Sulzmaier,
• John Timmer,
• Brendan Eckelman,
• Analeah Heidt,
• William Crago,
• Emily Rowell,
• Elisabeth Torretti

Affiliations

Quinn Deveraux

Aff653 grid.428605.dFive Prime Therapeutics South San Francisco CA USA

Heather Kinkead

Aff1 grid.21107.350000000121719311OncologyJohns Hopkins University Baltimore MD USA

Kyle Jones

2 Research Department of Infection and Population Health, University College London, London, UK

Bryan Becklund

Inhibrx, La Jolla, CA, United States

Florian Sulzmaier

Inhibrx, La Jolla, CA, United States

John Timmer

Inhibrx, La Jolla, CA, United States

Brendan Eckelman

Inhibrx, La Jolla, CA, United States

Analeah Heidt

Inhibrx, La Jolla, CA, United States

William Crago

Inhibrx Inc., La Jolla, CA, United States

Emily Rowell

Inhibrx, Inc., La Jolla, CA, USA

Elisabeth Torretti

Inhibrx, Inc., La Jolla, CA, USA